STOCK TITAN

Viridian Therapeutics (VRDN) Stock Price, News & Analysis

VRDN NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
21 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
+33.4% close of May 5, 2026
1-year change
+8.4% closing prices, November 13, 2025 to November 13, 2026
1-month change
+69.4% closing prices, October 13, 2026 to November 13, 2026

Company Description

Viridian Therapeutics, Inc. (Nasdaq: VRDN) is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases. According to company disclosures, Viridian applies its expertise in antibody discovery and protein engineering to create differentiated therapeutic candidates directed at previously validated drug targets in commercially established disease areas. The company is based in Waltham, Massachusetts and its common stock trades on The Nasdaq Stock Market LLC under the symbol VRDN.

Viridian’s lead area of focus is thyroid eye disease (TED), a rare autoimmune disorder affecting the tissues around the eyes. The company is advancing multiple anti–insulin-like growth factor-1 receptor (IGF‑1R) candidates in the clinic for TED across both active and chronic forms of the disease. Its pivotal TED program centers on veligrotug (also referred to as VRDN‑001), an intravenously delivered, anti‑IGF‑1R monoclonal antibody in late-stage development. Viridian has conducted two global phase 3 clinical trials, THRIVE and THRIVE‑2, designed to evaluate veligrotug’s efficacy and safety in patients with active and chronic TED, respectively. Company reports state that both trials met their primary and all secondary endpoints and showed a rapid onset of clinical benefit, including statistically significant and clinically meaningful effects on measures such as proptosis and diplopia, with veligrotug generally well tolerated.

Building on the veligrotug program, Viridian is also developing elegrobart (VRDN‑003), a subcutaneously delivered, half‑life extended anti‑IGF‑1R antibody. VRDN‑003 shares the same binding domain as veligrotug and has been engineered for a longer half‑life. It is being studied as a potential subcutaneous therapy for TED in two global phase 3 pivotal trials, REVEAL‑1 and REVEAL‑2, which evaluate dosing every four weeks and every eight weeks in patients with active and chronic TED. Company materials describe VRDN‑003 as designed for administration via a low‑volume autoinjector that patients could self‑administer at home, with dosing regimens intended to align with exposure levels associated with clinical activity observed for veligrotug in earlier studies.

Beyond IGF‑1R inhibition, Viridian is expanding its TED-focused pipeline with an anti–thyroid‑stimulating hormone receptor (TSHR) program. The company describes this program as a half‑life extended monoclonal antibody that inhibits TSHR and is designed for subcutaneous delivery in an autoinjector with extended dosing intervals. The TSHR program is being advanced as a potential therapy for TED or Graves disease, reflecting Viridian’s strategy of addressing multiple biologic drivers implicated in thyroid-related autoimmune conditions.

Viridian is also developing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors with potential application across multiple autoimmune diseases. This portfolio includes VRDN‑006, described as a highly selective Fc fragment that inhibits FcRn and is designed as a convenient subcutaneous, self‑administered option. In a phase 1 healthy volunteer trial, VRDN‑006 demonstrated proof‑of‑concept reductions in immunoglobulin G (IgG) consistent with the FcRn inhibitor class and was reported to spare albumin and low‑density lipoprotein (LDL), with the program described as generally well tolerated. Viridian’s second FcRn candidate, VRDN‑008, is characterized as a bi‑specific, half‑life extended FcRn inhibitor that combines an Fc fragment with an albumin‑binding domain. Preclinical data in non‑human primates disclosed by the company indicate that VRDN‑008 showed a longer half‑life and more sustained IgG reduction than efgartigimod after a single high‑dose head‑to‑head study.

Across these programs, Viridian emphasizes a development strategy that targets serious and rare conditions where validated biological pathways already exist, and where the company believes differentiated antibody engineering can yield therapeutic profiles that may be attractive to patients, physicians, and payers. In TED, Viridian’s clinical and regulatory efforts include late-stage intravenous and subcutaneous candidates, as well as plans for geographic expansion through regulatory submissions such as a Marketing Authorization Application to the European Medicines Agency, as described in company press releases. In addition, Viridian has entered into a collaboration and license agreement with Kissei Pharmaceutical Co., Ltd., granting Kissei an exclusive license to develop and commercialize products containing veligrotug and VRDN‑003 in Japan, with Viridian retaining manufacturing responsibilities for those products under specified circumstances and being eligible for upfront, milestone, and royalty payments.

Viridian’s disclosures also describe steps toward building commercial capabilities around its TED portfolio, including preparations for a potential U.S. launch of veligrotug and subsequent commercialization of VRDN‑003, subject to regulatory approvals. The company has discussed assembling leadership in areas such as sales, market access, patient services, and medical affairs, and focusing on a defined group of physicians who are key prescribers in the TED treatment landscape. Financing transactions, including public equity offerings, royalty financing agreements, and credit facilities, have been highlighted by Viridian as mechanisms to support its clinical programs and anticipated commercialization activities.

Overall, Viridian Therapeutics presents itself as a clinical-stage biopharmaceutical company with a concentrated focus on antibody-based therapies for serious and rare diseases, particularly thyroid eye disease and autoimmune conditions where modulation of IGF‑1R, TSHR, or FcRn pathways may provide clinical benefit. The company’s pipeline spans late-stage pivotal trials in TED and earlier-stage FcRn inhibitor programs, all underpinned by its stated capabilities in antibody discovery and protein engineering.

Business focus and therapeutic areas

According to Viridian’s public statements, the company’s core business focus includes:

  • Thyroid eye disease (TED): Development of intravenous and subcutaneous anti‑IGF‑1R antibodies (veligrotug and VRDN‑003/elegrobart) in global phase 3 clinical programs, and advancement of an anti‑TSHR monoclonal antibody program as a potential therapy for TED or Graves disease.
  • Autoimmune diseases: Advancement of a portfolio of FcRn inhibitors (VRDN‑006 and VRDN‑008) with potential application in multiple autoimmune conditions, supported by early clinical and preclinical data on IgG reduction and pharmacokinetic properties.
  • Antibody engineering: Use of antibody discovery and protein engineering expertise to generate differentiated candidates for validated targets, with an emphasis on half‑life extension, route of administration (intravenous vs. subcutaneous), and dosing schedules designed for patient convenience.

Regulatory and clinical development context

Viridian has reported several notable regulatory and clinical milestones for its TED programs. The company has stated that veligrotug received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for TED, and that the FDA accepted a Biologics License Application (BLA) for veligrotug with Priority Review and a Prescription Drug User Fee Act (PDUFA) target action date. The BLA is supported by data from the THRIVE and THRIVE‑2 phase 3 trials, which, according to Viridian, met all primary and secondary endpoints and demonstrated rapid onset of clinical benefit, including improvements in proptosis and diplopia, with veligrotug generally well tolerated.

For VRDN‑003/elegrobart, Viridian has described two ongoing global phase 3 pivotal clinical trials, REVEAL‑1 and REVEAL‑2, in active and chronic TED, respectively, assessing subcutaneous dosing every four or eight weeks. Company communications note that enrollment targets in these studies were exceeded, driven by what Viridian characterizes as strong patient demand, and that topline data readouts are planned on a defined timeline.

Collaborations and geographic reach

Viridian’s collaboration with Kissei Pharmaceutical Co., Ltd., as disclosed in an 8‑K filing, grants Kissei an exclusive license to develop and commercialize veligrotug and VRDN‑003 in Japan, including for potential treatment of TED. Under this agreement, Kissei is responsible for development and regulatory activities in Japan, while Viridian maintains certain manufacturing responsibilities and is eligible for upfront, milestone, and tiered royalty payments based on net sales in that territory. This collaboration illustrates Viridian’s approach to expanding the reach of its TED therapies beyond the United States through regional partnerships.

Stock listing and corporate governance

Viridian Therapeutics’ common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Stock Market LLC under the ticker symbol VRDN, as noted in multiple Form 8‑K filings. The company has an Amended and Restated 2016 Equity Incentive Plan and has disclosed shareholder approvals of amendments to increase the number of shares available for issuance under that plan, as well as the adoption of an employee stock purchase plan. Viridian also reports periodic inducement grants of stock options to new employees under Nasdaq Listing Rule 5635(c)(4), reflecting the use of equity-based compensation as part of its talent strategy.

Stock Performance

$30.87
+1.28%
+0.39
Last updated: November 13, 2026 at 16:00
+8.4%
Performance 1 year

Viridian Therapeutics (VRDN) closed at $30.87 on November 13, 2026. Over the past 12 months, the price has gained 8.4%.

See what a $1,000 investment in VRDN would be worth today

Average down calculator for VRDN

VRDN Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Viridian Therapeutics has 10 recent news articles, with the latest published 6 days ago. Of the recent coverage, 8 articles coincided with positive price movement and 2 with negative movement. Key topics include clinical trial, conferences, earnings, earnings date, fda approval. View all VRDN news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
14,212
Shares Sold
2
Transactions
Most Recent Transaction
Tousignant Jennifer (Chief Legal Officer) sold 14,212 shares at an average of $24.50 on August 19, 2026

Insider selling at Viridian Therapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Viridian Therapeutics generated $70.8M in revenue in FY2025, operating income reached -$363.4M, and net income was -$342.6M. The company generated -$276.4M in operating cash flow. The current ratio was 12.65, measuring current assets divided by current liabilities.

$70.8M
Revenue (FY2025)
-$342.6M
Net Income (FY2025)
-$276.4M
Operating Cash Flow

Upcoming Events

DEC
01
December 1, 2026 - December 1, 2029 Corporate

Options vesting period

171,900 inducement options vest 25% on 2026-12-01 then monthly over next 36 months; granted 2025-12-01
Q1
2027
Q1 2027 Regulatory

Elegrobart FDA decision

Targeted FDA approval decision for elegrobart expected in Q1 2027; approval would enable commercial launch and revenue recognition.
Q1
2027
Q1 2027 Regulatory

BLA submission for elegrobart

BLA submission to FDA for elegrobart is planned in Q1 2027; company said submission on track. No webcast/contact provided.
Q1
2027
Q1 2027 Regulatory

BLA anticipated

Company anticipates a BLA filing for elegrobart in Q1 2027; expect regulatory updates, filing notices and investor webcast (Viridian, VRDN).
Q1
2027
Q1 2027 Regulatory

BLA submission anticipated

Planned BLA submission for elegrobart to FDA; timing contingent on REVEAL-2 results.
Q1
2027
Q1 2027 Regulatory

elegrobart BLA submission

Planned BLA submission to FDA for elegrobart in Q1 2027 following positive REVEAL-1 and REVEAL-2 phase 3 results.
JAN
02
January 2, 2027 - January 2, 2030 Corporate

Option vesting schedule

16,650 options: 25% vests after 1 year, remaining 75% vests monthly over 36 months
YEAR
2027
2027 Clinical

registrational trial start

Planned placebo-controlled registrational trial in myasthenia gravis testing 4- and 8-week dosing; start mid-2027 pending regulatory feedback.

Viridian Therapeutics has 8 upcoming scheduled events. The next event, "Options vesting period", is scheduled for December 1, 2026 (in 16 days). Investors can track these dates to stay informed about potential catalysts that may affect the VRDN stock price.

Short Interest History

Last 12 Months

Short interest in Viridian Therapeutics (VRDN) currently stands at 17.0 million shares, down 5.3% from the previous reporting period, representing 15.1% of the float. Since November 2025, short interest has increased by 85.8%.

Days to Cover History

Last 12 Months

Days to cover for Viridian Therapeutics (VRDN) currently stands at 9.1 days, up 13.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 80.3%. Across the settlements charted above, it has ranged from 2.6 to 16.6 days.

VRDN Company Profile & Sector Positioning

Viridian Therapeutics (VRDN) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing VRDN often look at related companies in the same sector, including Disc Medicine, Inc. (IRON), Enliven Therapeutics, Inc. (ELVN), Iovance Biotherapeutics, Inc. (IOVA), Arcutis Biotherapeutics, Inc. (ARQT), and Legend Biotech Corporation (LEGN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate VRDN's relative position within its industry.

Frequently Asked Questions

The current stock price of Viridian Therapeutics (VRDN) is $30.87 as of November 13, 2026.

The market cap of Viridian Therapeutics (VRDN) is approximately $3.5B. Learn more about what market capitalization means .

The FY2025 revenue of Viridian Therapeutics (VRDN) is $70.8M, from its most recent completed fiscal year.

The FY2025 net income of Viridian Therapeutics (VRDN) is -$342.6M, from its most recent completed fiscal year.

The operating cash flow of Viridian Therapeutics (VRDN) is -$276.4M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Viridian Therapeutics (VRDN), current assets divided by current liabilities, was 12.65 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Viridian Therapeutics (VRDN) is -$363.4M for FY2025, its most recent completed fiscal year. Learn about operating income.

Viridian Therapeutics focuses on discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases. The company emphasizes antibody discovery and protein engineering to create differentiated therapeutic candidates for validated drug targets, with a particular focus on thyroid eye disease and autoimmune conditions involving IGF‑1R, TSHR, and FcRn pathways.

Viridian’s lead programs target thyroid eye disease (TED), a rare autoimmune disorder affecting tissues around the eyes. The company is developing intravenous and subcutaneous anti‑IGF‑1R antibodies, veligrotug and VRDN‑003/elegrobart, for active and chronic TED, and an anti‑TSHR monoclonal antibody program as a potential therapy for TED or Graves disease. Its FcRn inhibitor portfolio is intended for development in multiple autoimmune diseases.

Veligrotug is in late-stage development for thyroid eye disease. Viridian has conducted two global phase 3 clinical trials, THRIVE and THRIVE‑2, in active and chronic TED patients. According to the company, both trials met their primary and all secondary endpoints, demonstrated rapid onset of clinical benefit on measures such as proptosis and diplopia, and showed that veligrotug was generally well tolerated. The U.S. FDA has accepted a Biologics License Application for veligrotug with Priority Review.

VRDN‑003, also known as elegrobart, is a subcutaneously delivered, half‑life extended anti‑IGF‑1R antibody that shares the same binding domain as veligrotug but has been engineered for a longer half‑life. While veligrotug is administered intravenously, VRDN‑003 is being developed for subcutaneous administration, with phase 3 trials REVEAL‑1 and REVEAL‑2 evaluating every‑four‑week and every‑eight‑week dosing in patients with active and chronic thyroid eye disease.

Viridian’s FcRn inhibitor portfolio focuses on modulating the neonatal Fc receptor to reduce IgG levels in autoimmune diseases. VRDN‑006 is a highly selective Fc fragment that inhibits FcRn and is designed for convenient subcutaneous self‑administration; in a phase 1 healthy volunteer trial it showed IgG reduction consistent with the FcRn inhibitor class and spared albumin and LDL. VRDN‑008 is a bi‑specific, half‑life extended FcRn inhibitor with an albumin‑binding domain, and in non‑human primate studies it showed a longer half‑life and more sustained IgG reduction than efgartigimod.

Viridian Therapeutics is based in Waltham, Massachusetts. Its common stock, with a par value of $0.01 per share, is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Stock Market LLC under the ticker symbol VRDN, as disclosed in multiple Form 8‑K filings.

Yes. Viridian has a Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. Under this agreement, Kissei holds an exclusive license to develop and commercialize products containing veligrotug and VRDN‑003 in Japan and a non‑exclusive license to manufacture those products for use in Japan under certain circumstances. Viridian is eligible for an upfront payment, development, regulatory and sales milestones, and tiered royalties on net sales, while retaining certain manufacturing responsibilities.

Viridian describes a commercial strategy that includes preparing for potential U.S. launches of veligrotug and VRDN‑003, subject to regulatory approvals, and building commercial infrastructure in areas such as sales, market access, patient services, and medical affairs. Company communications reference a focus on a defined group of core prescribers in the thyroid eye disease treatment landscape and market research assessing physician and payer perspectives on its investigational product profiles.